Radium-223 therapy in metastatic castration-resistant prostate cancer: baseline predictors of treatment completion and survival in a reimbursement-regulated Taiwanese cohort.
- DOI
- 10.1007/s12149-026-02284-z
- Published
- 2026-09-15
- Container
- Ann Nucl Med
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12149-026-02284-z,
title = {Radium-223 therapy in metastatic castration-resistant prostate cancer: baseline predictors of treatment completion and survival in a reimbursement-regulated Taiwanese cohort.},
author = {Tsai HC and Tseng JR and Liu FY and Wu CT and Yu KJ and Su PJ and Ho KC.},
year = {2026},
journal = {Ann Nucl Med},
doi = {10.1007/s12149-026-02284-z},
url = {https://doi.org/10.1007/s12149-026-02284-z}
}RIS
TY - JOUR TI - Radium-223 therapy in metastatic castration-resistant prostate cancer: baseline predictors of treatment completion and survival in a reimbursement-regulated Taiwanese cohort. AU - Tsai HC AU - Tseng JR AU - Liu FY AU - Wu CT AU - Yu KJ AU - Su PJ AU - Ho KC. PY - 2026 JO - Ann Nucl Med DO - 10.1007/s12149-026-02284-z UR - https://doi.org/10.1007/s12149-026-02284-z ER -
APA
HC, T., JR, T., FY, L., CT, W., KJ, Y., PJ, S., & KC., H. (2026). Radium-223 therapy in metastatic castration-resistant prostate cancer: baseline predictors of treatment completion and survival in a reimbursement-regulated Taiwanese cohort.. Ann Nucl Med. https://doi.org/10.1007/s12149-026-02284-z
Source records
- europe-pmc · retrieved 2026-09-27T10:30:18.268Z